keangkong
GLP-1 Specialist
- Member Since
- Sep 2, 2024
- Posts
- 1,884
- Likes Received
- 4,961
Bhattachar, et al. (2025). 882-P - Eloralintide, a Selective, Long-Acting Amylin Receptor Agonist for Obesity—Phase 1 Proof of Concept. Diabetes 74, Issue Supplement_1. https://diabetesjournals.org/diabetes/article/74/Supplement_1/882-P/159628.
Billings, et al. (pre-publication, 2025). Eloralintide, a selective amylin receptor agonist for the treatment of obesity - a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet, doi-10.1016/S0140-6736(25)02155-5. https://1drv.ms/b/c/d63cedb6db1eefc3/Efm5F9RRts5JnrKihcpJoN0B1BE1tSjoKK_VUYjg43vc4Q?e=potceA.
Briere, et al. (2025). Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity - From discovery to clinical proof of concept. Molecular Metabolism 102, 102271. https://1drv.ms/b/c/d63cedb6db1eefc3/EZx6P3tA15lJuCMGxqzAafsB1DY88CHuJlvKjk3iMUc3cA?e=lqQta3.
Hsia, et al (Obesity Week 2025). Poster - Eloralintide Phase 2 Study in Adult Participants With Overweight or Obesity - Design and Study Population. https://assets.ctfassets.net/mpejy6...AYS_ELORALINTIDE_SYMPOSIUM_DV-033298_V3.2.pdf.
Knapp (Nov. 6, 2025). Eloralintide Lilly’s Amylin Agonist Outperforms Novo’s Cagrilintide at 48 Weeks. On The Pen. https://www.onthepen.com/post/elora...t-outperforms-novo-s-cagrilintide-at-48-weeks.
Lee (2025). A Review of Amylin Peptide Receptor Activators for Obesity Pharmacotherapy. Curr. Drug Targets 26, 980-991. https://1drv.ms/b/c/d63cedb6db1eefc3/ESfcsFAE-MJCjCjvlRm3cZIBcLSzSs7gaZXsYh4KuGCAbA?e=bxIoK8.
Mullard (2025). Amylin takes another shot at the obesity prize - Drug developers are re-advancing amylin analogues for obesity, two decades since the FDA approved the first of these hormone mimetics for diabetes. Nature Rev. Drug Discovery 24, 403-406. https://1drv.ms/b/c/d63cedb6db1eefc3/EblzZa0fnghDlrbKIi5EzKIBU3CLaP44pBBa1pwWqYgw8A?e=c4hUCd.
Billings, et al. (pre-publication, 2025). Eloralintide, a selective amylin receptor agonist for the treatment of obesity - a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet, doi-10.1016/S0140-6736(25)02155-5. https://1drv.ms/b/c/d63cedb6db1eefc3/Efm5F9RRts5JnrKihcpJoN0B1BE1tSjoKK_VUYjg43vc4Q?e=potceA.
Briere, et al. (2025). Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity - From discovery to clinical proof of concept. Molecular Metabolism 102, 102271. https://1drv.ms/b/c/d63cedb6db1eefc3/EZx6P3tA15lJuCMGxqzAafsB1DY88CHuJlvKjk3iMUc3cA?e=lqQta3.
Hsia, et al (Obesity Week 2025). Poster - Eloralintide Phase 2 Study in Adult Participants With Overweight or Obesity - Design and Study Population. https://assets.ctfassets.net/mpejy6...AYS_ELORALINTIDE_SYMPOSIUM_DV-033298_V3.2.pdf.
Knapp (Nov. 6, 2025). Eloralintide Lilly’s Amylin Agonist Outperforms Novo’s Cagrilintide at 48 Weeks. On The Pen. https://www.onthepen.com/post/elora...t-outperforms-novo-s-cagrilintide-at-48-weeks.
Lee (2025). A Review of Amylin Peptide Receptor Activators for Obesity Pharmacotherapy. Curr. Drug Targets 26, 980-991. https://1drv.ms/b/c/d63cedb6db1eefc3/ESfcsFAE-MJCjCjvlRm3cZIBcLSzSs7gaZXsYh4KuGCAbA?e=bxIoK8.
Mullard (2025). Amylin takes another shot at the obesity prize - Drug developers are re-advancing amylin analogues for obesity, two decades since the FDA approved the first of these hormone mimetics for diabetes. Nature Rev. Drug Discovery 24, 403-406. https://1drv.ms/b/c/d63cedb6db1eefc3/EblzZa0fnghDlrbKIi5EzKIBU3CLaP44pBBa1pwWqYgw8A?e=c4hUCd.
